Presented by: Mrs. Smart-Patterson

Wiley College Spring 2016

Bio Seminar II

An interpretation of results with Syncardia Total Artificial Heart

ASAIO Journal: American Society of Artificial Internal OrgansNovember/December 2014 - Volume 60 - Issue 6 - p 626–634

doi: 10.1097/MAT.0000000000000132

Adult Circulatory Support

Published

Gianluca Torregrossa, Michiel Morshuis,Robin Varghese, Leila Hosseinian, Vladimiro Vida,

Vincenzo Tarzia,Antonio Loforte,Daniel Duveau,Francisco Arabia, Pascal Leprince,Vigneshwa Kasirajan,

Friedhelm Beyersdorf, Francesco Musumeci, Roland Hetzer, Thoamas Krabatsch,

Jan Gummert,Jack Copeland and Gino Gerosa

Authors

Origin Data Collected

Age Support Period

Primary Diagnosis

Dec. 2011 Survival Rate

Infections

Thromboembolic

Hemorrhagic

Device Failure

Anti-thrombic Therapy

50 + - 1.57years

554 days Dilated cardiomyopathy(23)

Ischemic (15)

Other (9)

Introduction

criteria

• Syncardia TAH device• For at least 1 year

criteria

• Obtained between 1989-2011• Data complete and Fully Available

criteria

• At least had 1 of the INTERMATICS class (1-3)• BSA of at least 1.7• Anterior/posterior mediastinum of 10cm

Method

1 year post Syncardia TAH

successful

Died

currently supported

device failure

Results

Reliable and effective in replacing the entire heart

Patients supported for at least 1 year with Syncardia TAH:

-TAH device leading cause of death (2 cases)

-Primary cause of death: Infections and Hemorrhagic.

Conclusion

Q & A